ASCO24

Guillermo Garcia-Manero, MDMyelodysplastic Syndromes | October 24, 2024
Dr. Garcia-Manero discusses the latest updates from the COMMANDS trial.
Olalekan Oluwole, MDMeeting News | July 3, 2024
Dr. Oluwole discussed new data on brexu-cel in patients with relapsed or refractory ALL.
Paula Rodríguez Otero, MDMeeting News | July 1, 2024
Dr. Rodríguez-Otero shares the MRD analysis from the phase III PERSEUS trial at the 2024 ASCO Annual Meeting.
Advertisement
Melissa BadamoMantle Cell Lymphoma | July 31, 2024
The study compared treatment response based on prior systemic lines of therapy and prior BTK inhibition in patients with MCL.
Melissa BadamoMyelofibrosis | July 1, 2024
Julie Braish, MBBCh, discusses her study on JAK2 allele burden in myelofibrosis presented at ASCO 2024.
Andrew MorenoMyelodysplastic Syndromes | June 26, 2024
A phase II study evaluated a combination of the IMM01 fusion protein with azacitidine in untreated MDS.
Advertisement
Andrew MorenoMyelodysplastic Syndromes | June 27, 2024
A database analysis compares how much time patients spend in healthcare settings, based on receiving oral, IV, or SC HMAs.
Yucai Wang, MD, PhDMantle Cell Lymphoma | June 14, 2024
After five and a half years of follow-up, rituximab maintenance significantly improved survival outcomes.
Melissa BadamoVideo Insights | June 12, 2024
Dr. El-Jawahri discusses exciting ASCO sessions, such as the plenary session that focused on telehealth and palliative care.
Mazyar Shadman, MD, MPHChronic Lymphocytic Leukemia | June 12, 2024
The study utilized three clinical trials to compare the efficacy of acalabrutinib, zanubrutinib, and ibrutinib for CLL.
Fateeha Furqan, MDChronic Lymphocytic Leukemia | June 10, 2024
Dr. Furqan shared data from a retrospective analysis on patients who received pirtobrutinib prior to CAR T-cell therapy.
Andrew MorenoAcute Lymphoblastic Leukemia | June 6, 2024
Investigators identified pre- and postinfusion factors linked to severe hematotoxicity, as defined by EHA/EBMT criteria.
Manali Kamdar, MDTransplantation & Cellular Therapy | August 23, 2024
Manali Kamdar, MD, shared results from the pivotal phase III TRANSFORM study on lisocabtagene maraleucel in LBCL.
Andrew MorenoAggressive B-Cell Lymphoma | June 6, 2024
A retrospective study has found an association between post-CAR-T sC5b-9 levels and ICANS occurrence following CAR-T.
Lakshmi Nayak, MDAggressive B-Cell Lymphoma | June 4, 2024
These findings concern axi-cel use in relapsed and refractory primary and secondary disease.
Luciano Costa, MDMyeloma | June 3, 2024
Dr. Costa presents subgroup findings from the single-line therapy patients in the CARTITUDE-4 phase III trial.
Melissa BadamoAggressive B-Cell Lymphoma | June 3, 2024
Patients with relapsed refractory LBCL can derive clinical benefit from liso-cel NCP without compromising safety.
Melissa BadamoAcute Myeloid Leukemia | June 3, 2024
Patients who responded to treatment achieved more than 90% bone marrow blast reduction compared with baseline.
Guillermo Garcia-Manero, MDMyelodysplastic Syndromes | June 4, 2024
Dr. Garcia-Manero discussed the phase II ASTREON trial on myelodysplastic syndromes at the 2024 ASCO Annual Meeting.
Advertisement
Advertisement
Editorial Board